Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer?
Authors:
Open Access
- 29 January 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (4) , 292-e548
Abstract
Lessons Learned Despite U.S. Food and Drug Administration approval to reduce alopecia, data on efficacy of scalp cooling in Black patients with cancer are limited by lack of minority representation in prior clinical trials. Scalp cooling devices may have less efficacy in Black patients; additional studies are required to explore the possible causes for this, including hair texture and cap design. Background The Paxman scalp cooling (SC) device is U.S. Food and Drug Administration (FDA)‐approved for prevention of chemotherapy‐induced alopecia. Studies report 50%–80% success rates and high patient satisfaction, yet there have been no studies of SC in Black patients. We conducted a phase II feasibility study of Paxman SC with a planned enrollment of 30 Black patients receiving chemotherapy for stage I–III breast cancer. Methods Black patients who planned to receive at least four cycles of chemotherapy with non‐anthracycline (NAC) or anthracycline (AC) regimens were eligible. Alopecia was assessed by trained oncology providers using the modified Dean scale (MDS) prior to each chemotherapy session. Distress related to alopecia was measured by the Chemotherapy Alopecia Distress Scale (CADS). Results Fifteen patients enrolled in the intervention before the study was closed early because of lack of efficacy. Median MDS and CADS increased after SC, suggesting increased hair loss (p < .001) and alopecia distress (p = .04). Only one participant was successful in preventing significant hair loss; the majority stopped SC before chemotherapy completion because of grade 3 alopecia (>50% hair loss). Conclusion SC may not be efficacious in preventing alopecia in Black women. Differences in hair thickness, hair volume, and limitations of cooling cap design are possible contributing factors.Keywords
This publication has 9 references indexed in Scilit:
- The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic reviewBreast Cancer Research and Treatment, 2019
- Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapySupportive Care in Cancer, 2018
- Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline/taxane-based chemotherapyThe Breast, 2018
- Management of Chemotherapy-Induced Alopecia With Scalp CoolingJournal of Oncology Practice, 2018
- Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysisBreast Cancer Research and Treatment, 2017
- Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast CancerJAMA, 2017
- Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patientsAnnals of Oncology, 2013
- Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - Results of the Dutch Scalp Cooling RegistryActa Oncologica, 2012
- Prevention of Doxorubicin-Induced Hair Loss with Scalp HypothermiaNew England Journal of Medicine, 1979